Lipid-lowering effects of statins: a comparative review
- 23 August 2006
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 7 (13) , 1701-1714
- https://doi.org/10.1517/14656566.7.13.1701
Abstract
The pharmacological regulation of lipid metabolism in patients with dyslipidaemia is unequivocally associated with significant reductions in risk for cardiovascular morbidity and mortality. There is strong clinical trial data to support of the use of statin therapies in the settings of both primary and secondary prevention. This paper addresses: i) the mechanisms of action of antilipidaemic medications; ii) dosing regimens and the pharmacokinetic differences among drugs of the same class; iii) risk for drug interactions; and iv) reviews the clinical trial evidence used to support the use of particular antilipidaemic medications in specific physiological settings.Keywords
This publication has 62 references indexed in Scilit:
- Statin Safety: An Overview and Assessment of the Data—2005The American Journal of Cardiology, 2006
- An Assessment of Statin Safety by Muscle ExpertsThe American Journal of Cardiology, 2006
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin)The American Journal of Cardiology, 2006
- Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) StudyAmerican Heart Journal, 2005
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)The American Journal of Cardiology, 2005
- Introduction: rosuvastatin—an efficacy assessment based on pooled trial dataThe American Journal of Cardiology, 2003
- Clinical Pharmacokinetics of FluvastatinClinical Pharmacokinetics, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juiceLife Sciences, 1996